Mercados españoles cerrados en 1 hr 28 mins

Valneva SE (VLA.PA)

Paris - Paris Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
6,55+0,29 (+4,66%)
A partir del 03:44PM CET. Mercado abierto.

Valneva SE

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo762

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Thomas LingelbachChairman of the Management Board, Pres & CEO769,14kN/A1963
Mr. Franck Grimaud MBADirector Gen., Chief Bus. Officer & Member of Management Board482,35kN/A1967
Mr. Frederic JacototVP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board378,59kN/A1965
Dr. Juan-Carlos Jaramillo M.D.Chief Medical Officer & Member of the Management Board527,17kN/A1971
Mr. Peter BuhlerCFO & Management Board MemberN/AN/A1971
Mr. Perry CelentanoInterim Chief Operating OfficerN/AN/AN/A
Ms. Dipal PatelChief Commercial Officer & Member of Management BoardN/AN/AN/A
Mr. Joshua Drumm Ph.D.VP of Investor RelationsN/AN/AN/A
Ms. Laetitia Bachelot-FontaineVP of Global Communications & European Investor RelationsN/AN/AN/A
Mr. Gerald StrohmaierVP of Human ResourceN/AN/AN/A
Los importes son a partir de 31 de diciembre de 2021 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.

Gobierno corporativo

El ISS Governance QualityScore de Valneva SE, a día 28 de noviembre de 2022, es 10. Las puntuaciones base son Auditoría: 10; Tablero: 8; Derechos de los accionistas: 6; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.